Author

Paul Greaves

Observed names: P. Greaves, Paul J. Greaves

Institution: Barking, Havering And Redbridge University Hospitals NHS Trust

Observed institutions: National Health Service, Barking, Havering And Redbridge University Hospitals NHS Trust, National Institutes of Health, St Bartholomew's Hospital, Queen Mary University of London, Barts Health NHS Trust, The Royal Free Hospital, Royal London Hospital, University of Oxford, Homerton University Hospital, Homerton University Hospital NHS Foundation Trust, Queen's Hospital, Queen's Hospital, National Institutes of Health Clinical Center, Barts Cancer Institute

ORCID: 0000-0002-3318-7233

Observed ORCID: 0000-0002-3318-7233

OpenAlex ID: A5091780580

COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study

2020 · Lennard Y W Lee, Jean-Baptiste Cazier, et al. · The Lancet Oncology · 590

PDF

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2021 · Eugenia Abaleke, Mustafa Abbas, et al. · The Lancet · 562

PDF

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 508

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 393

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 354

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 302

The role of B7 family molecules in hematologic malignancy

2012 · Paul Greaves, John G. Gribben · Blood · 195

Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells

2013 · Paul Greaves, Andrew Clear, et al. · Blood · 163

Expression of FOXP3, CD68, and CD20 at Diagnosis in the Microenvironment of Classical Hodgkin Lymphoma Is Predictive of Outcome

2012 · Paul Greaves, Andrew Clear, et al. · Journal of Clinical Oncology · 150

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

2023 · Obbina Abani, Ali Abbas, et al. · The Lancet · 139

Bone marrow necrosis and fat embolism syndrome in sickle cell disease: Increased susceptibility of patients with non-SS genotypes and a possible association with human parvovirus B19 infection

2014 · Dimitris A. Tsitsikas, Giorgio Gallinella, et al. · Blood Reviews · 131

Fertility and sexual function in long‐term survivors of haematological malignancy: using patient‐reported outcome measures to assess a neglected area of need in the late effects clinic

2013 · Paul Greaves, Shah‐Jalal Sarker, et al. · British Journal of Haematology · 73

PDF

Revisiting the immune microenvironment of diffuse large B-cell lymphoma using a tissue microarray and immunohistochemistry: robust semi-automated analysis reveals CD3 and FoxP3 as potential predictors of response to R-CHOP

2014 · R. Coutinho, A. J. Clear, et al. · Haematologica · 65

PDF

The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies

2013 · Konstantinos Liapis, Andrew Clear, et al. · Blood · 58

Psychosocial factors associated with impact of cancer in longterm haematological cancer survivors

2013 · Ania Korszun, Shah‐Jalal Sarker, et al. · British Journal of Haematology · 43

PDF

Management of secondary central nervous system lymphoma

2022 · Kate Cwynarski, Thomas Cummin, et al. · British Journal of Haematology · 28

A retrospective study of MYC rearranged diffuse large B-cell lymphoma in the context of the new WHO and ICC classifications

2023 · Dima El-Sharkawi, Amit Sud, et al. · Blood Cancer Journal · 21

PDF

Successful outcome of three patients with sickle‐cell disease and fat embolism syndrome treated with intensive exchange transfusion

2016 · Paul Greaves, Vivek Mathew, et al. · Clinical Case Reports · 20

PDF

Sweet syndrome as terminal event in ruxolitinib‐treated myelofibrosis

2015 · Basabi Chatterjee, Usama Rqieh, et al. · British Journal of Haematology · 15

Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse

2012 · S. Montoto, J. Matthews, et al. · Haematologica · 14

PDF

A randomised evaluation of low‐dose cytosine arabinoside (ara‐C) plus tosedostat versus low‐dose ara‐C in older patients with acute myeloid leukaemia: results of the LI‐1 trial

2021 · Mike Dennis, Alan Burnett, et al. · British Journal of Haematology · 11

PDF

Addition of plasma exchange to red cell exchange improves outcomes of fat embolism syndrome in sickle cell disease

2023 · Dimitris A. Tsitsikas, Susan Rowe, et al. · British Journal of Haematology · 10

PDF

Posterior reversible encephalopathy syndrome following anti‐lymphocyte globulin treatment for severe aplastic anaemia

2006 · Paul Greaves, Heather Oakervee, et al. · British Journal of Haematology · 10

Early relapse and refractory disease remain risk factors in the anthracycline and autologous transplant era for patients with relapsed/refractory classical Hodgkin lymphoma: a single centre intention‐to‐treat analysis

2012 · Paul Greaves, Andrew Wilson, et al. · British Journal of Haematology · 9

Impact of MYC and BCL2 double expression on outcomes in primary CNS lymphoma: a UK multicenter analysis

2023 · Edward Poynton, Emily Chernucha, et al. · Blood Advances · 6

Works count: 55

Citation count: 3,902

H-index: 18

I10-index: 23